All
Physical Performance Predicts Outcomes in CAR T-Cell Therapy in NHL
Poor physical performance in patients with non-Hodgkin lymphoma receiving CAR T-cell therapy was linked to worse survival and increased risk of neurotoxicity in a cohort study.
Assessing the Need for Extended Monitoring After Axi-Cel Infusion
Olalekan O Oluwole, MD, MBBS, discusses the background and rationale of the research he contributed to, which was presented at the 2025 Transplantation & Cellular Therapy Meetings.
CAR T-Cell Therapy Effective Across Ages in Large B-Cell Lymphoma
CAR T-cell therapy showed efficacy in relapsed large B-cell lymphoma across age groups, including patients 70 and 80 years or older.
Avelumab Maintenance With Axitinib Interruption Feasible in Kidney Cancer
Avelumab maintenance with axitinib interruption was feasible in metastatic renal cell carcinoma responders, according to updated phase 2 TIDE-A study results.
FDA Fast-Tracks IBI363 in Squamous NSCLC
The FDA granted fast track status to IBI363 for the treatment of patients with advanced squamous lung cancer after prior treatment.
NXC-201 Earns FDA RMAT Designation in AL Amyloidosis
Proactive Onco-Coaching Improves Survival in Metastatic Kidney Cancer
Proactive onco-coaching did not improve quality of life but was linked to better overall survival in patients with metastatic renal cell carcinoma.
Higher Tivozanib Dose Improves Antitumor Activity in Kidney Cancer
Tivozanib at 1.34 mg showed greater antitumor activity than 0.89 mg, with similar hypertension rates, in kidney cancer.
Relugolix Shows Strong Adherence in Medicare Patients With Prostate Cancer
Over 90% adherence to relugolix in patients with Medicare with prostate cancer for 24 months supports its use as androgen deprivation therapy, per real-world study data.
Avelumab Maintenance Therapy Enhances Survival in Advanced Urothelial Cancer
Avelumab plus best supportive care improved survival vs best supportive care alone in advanced urothelial carcinoma, regardless of diabetes status.
Enfortumab Vedotin Improves Outcomes in Advanced Urothelial Cancer
Third-line enfortumab vedotin improved outcomes in metastatic urothelial carcinoma, per real-world data from the EV-301 trial.
Oral Relugolix Preferred Over Injectables in Advanced Prostate Cancer
OPTYX study shows many patients with advanced prostate cancer preferred oral relugolix over injectables for androgen deprivation therapy.
Lenvatinib Plus Pembrolizumab Shows Activity in Kidney Cancer
Lenvatinib plus pembrolizumab showed activity and a favorable safety profile in nonmetastatic clear cell renal cell carcinoma, per phase 2 study results.
Cemiplimab Plus Chemo Shows Benefit in Advanced Penile Cancer
Cemiplimab plus chemotherapy showed efficacy and consistent safety in advanced penile cancer in the phase 2 EPIC trial.
FDA Grants OPN-6602 Orphan Drug Status in R/R Myeloma
The FDA granted orphan drug designation to OPN-6602 for the potential treatment of relapsed/refractory multiple myeloma.
Idecabtagene Vicleucel Shows Strong Response in Multiple Myeloma
Idecabtagene vicleucel induced high complete response and minimal residual disease negativity rates in multiple myeloma after suboptimal first-line therapy.
Navigating the Use of Bispecific Antibodies and CAR T-Cell Therapy in RRMM
Binod Dhakal, MD, MS, discussed the use of bispecific antibodies and chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma treatment.
The Targeted Pulse: The Latest FDA Actions Across Cancer Types and Exploring the Efficiency of Remote Pharmacists in Community Oncology
The FDA makes furthering moves in SCLC, ovarian, and breast cancers, and the value of remote clinical pharmacists is explored in community oncology.
Tivozanib Plus Nivolumab Matches Monotherapy in Patient-Reported Outcomes
Tivozanib plus nivolumab had similar patient-reported outcomes to tivozanib alone in advanced kidney cancer after prior treatment, according to the TiNivo-2 study.
Belzutifan Plus Cabozantinib Shows Lasting Benefit in Kidney Cancer
Belzutifan plus cabozantinib maintained durable antitumor activity in advanced clear cell renal cell carcinoma, per phase 3 LITESPARK-003 data.
Cabozantinib Combo Sustains PFS Benefit in Advanced Kidney Cancer
Cabozantinib plus nivolumab and ipilimumab maintained a progression-free survival benefit at 45 months vs placebo in advanced kidney cancer.
Orca-T Shows Survival Benefit Over Cyclophosphamide in Transplant Study
Orca-T improved overall survival vs post-transplant cyclophosphamide in a retrospective analysis.
Nivolumab Plus Cabozantinib Improves Outcomes in Advanced Kidney Cancer
Nivolumab plus cabozantinib improved long-term efficacy and safety vs sunitinib in advanced renal cell carcinoma, per final CheckMate 9ER trial results.
Lenvatinib Plus Belzutifan Shows Activity in Advanced Kidney Cancer
Lenvatinib plus belzutifan showed durable activity and a consistent safety profile in advanced clear cell renal cell carcinoma after prior treatment.
Ciltacabtagene Autoleucel Improves Outcomes in Multiple Myeloma
Ciltacabtagene autoleucel improved minimal residual disease negativity and sustained responses vs standard care in lenalidomide-refractory multiple myeloma.
Obecabtagene Autoleucel Improves Survival in B-Cell Acute Leukemia
Obecabtagene autoleucel improved survival and response durability in B-cell acute lymphoblastic leukemia patients with minimal residual disease–negative remission.
Orca-T Shows Safety, Feasibility in Reduced-Intensity Stem Cell Transplant
Orca-T with reduced-intensity stem cell transplantation was a safe, feasible alternative to conventional transplant in blood cancers, per phase 1 data.
Enfortumab Vedotin Combo Doubles PFS vs Chemo in Urothelial Cancer
Enfortumab vedotin plus pembrolizumab doubled progression-free survival vs chemotherapy in urothelial cancer.
Datopotamab Deruxtecan Shows Promise in Advanced Urothelial Cancer
Datopotamab deruxtecan showed promising activity in advanced urothelial cancer in a phase 1 study.
UGN-102 Shows Lasting Responses in Low-Grade, Intermediate-Risk NMIBC
UGN-102 led to durable responses in low-grade, intermediate-risk bladder cancer, per phase 3 study findings at the 2025 Genitourinary Cancers Symposium.